PP
BMY.RT

Paloma Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Paloma Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,193
Closed -$8K – 2673
2020
Q2 		$8K Sell
2,193
-90,000
-98% -$325K ﹤0.01% 2042
2020
Q1 		$350K Sell
92,193
-497,209
-84% -$1.64M 0.02% 624
2019
Q4 		$1.77M Buy
+589,402
New +$1.53M 0.03% 643

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Paloma Partners's BMY.RT Position: Q3 2020 in Review

Paloma Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 2,193 shares — an estimated $8K sold.

Paloma Partners first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $1.77M in Q4 2019. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Paloma Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 2,193 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $8K.
  • Paloma Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • Paloma Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.77M in Q4 2019.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.